Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biocon Reports Profits Of INR74 crore
Biocon has announced a three-fold increase in profit at INR74 crore for the quarter ended 30 September, up from INR25 crore in the same period last year.The company’s
Biocon has announced a three-fold increase in profit at INR74 crore for the quarter ended 30 September, up from INR25 crore in the same period last year.The company’s
Potentia Pharmaceuticals it has entered into licensing and purchase option agreements with Alcon Research, a wholly-owned subsidiary of Alcon. The agreements provide Alcon with a license to develop
IRIS International has received Institutional Review Board (IRB) approvals from Duke University Medical Center, Memorial Sloan Kettering Cancer Institute, Eastern Virginia Medical School and the University of Washington
Impax Pharmaceuticals (Impax) has initiated a multinational phase III trial of its late-stage drug candidate IPX066 in advanced parkinson’s disease (PD) patients. IPX066 is an investigational extended release
Quark Pharmaceuticals (Quark) has reported the issuance of Japanese Patent Number: 4354633, titled, ‘Hypoxia regulated genes,’ on August 7, 2009. Granted to Quark from a Japanese National Phase
Boehringer Ingelheim has closed its deal with Pfizer to acquire a portion of the Fort Dodge Animal Health business. The acquisition, which includes products in the US, Australia,
Stellar Pharmaceuticals (Stellar) has signed a licensing agreement for the distribution and sale of Uracyst (a sterile sodium chondroitin sulfate solution, 2%) for the treatment of interstitial cystitis/painful
EpiCept is expected to release the new findings demonstrating the pharmacoeconomic benefits of Ceplene (histamine dihydrochloride) for the remission maintenance of Acute Myeloid Leukemia (AML) patients in first
Apogee Technology has announced the publication of an article on its intradermal immunization approach in the Online Early Edition of PNAS (the Proceedings of the National Academy of
Sanofi-Aventis has sealed a deal with Minsheng Pharmaceutical, based in Hangzhou, China, to set up a joint venture for the production of vitamin and mineral supplements. The burgeoning